- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (13)
38 result(s) found for: Total body irradiation.
Displaying page 1 of 2.
EudraCT Number: 2007-002548-12 | Sponsor Protocol Number: TJB0702 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:CHU-ULG | |||||||||||||
Full Title: Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings | |||||||||||||
Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003683-54 | Sponsor Protocol Number: OSHO #76 | Start Date*: 2008-06-18 |
Sponsor Name:GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH | ||
Full Title: Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbest... | ||
Medical condition: Patients suffering from leukemia (acute or chronic), receiving allogenic blood stem cell transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003736-77 | Sponsor Protocol Number: E7080-A001-216 | Start Date*: 2023-03-28 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | ||
Medical condition: Recurrent and Refractory Solid Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001238-32 | Sponsor Protocol Number: ADVL1622 | Start Date*: 2019-09-26 |
Sponsor Name:National Cancer Institute Cancer Therapy Evaluation | ||
Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | ||
Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-005098-19 | Sponsor Protocol Number: 1414-ROG-GUCG | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localiz... | |||||||||||||
Medical condition: very high risk localized or locally advanced prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Restarted) FR (Completed) AT (Completed) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001282-17 | Sponsor Protocol Number: E7389-G000-223 | Start Date*: 2018-03-23 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S... | ||
Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-003779-32 | Sponsor Protocol Number: NL77171.091.21 | Start Date*: 2021-09-27 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study). | ||
Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002054-37 | Sponsor Protocol Number: 1000053649 | Start Date*: 2019-09-18 | |||||||||||||||||||||
Sponsor Name:Hospital for Sick Children | |||||||||||||||||||||||
Full Title: Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers | |||||||||||||||||||||||
Medical condition: HYPERMUTANT CANCERS | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004800-23 | Sponsor Protocol Number: RG-17-241 | Start Date*: 2018-06-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in co... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukaemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003514-34 | Sponsor Protocol Number: HCTvs.CTelderlyAML | Start Date*: 2009-03-26 | |||||||||||
Sponsor Name:European Society for Blood and Marrow Transplantation EBMT | |||||||||||||
Full Title: A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as co... | |||||||||||||
Medical condition: Acute Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002609-78 | Sponsor Protocol Number: ETOP4-12/CA184-310 | Start Date*: 2015-02-17 | |||||||||||
Sponsor Name:ETOP (European Thoracic Oncology Platform) | |||||||||||||
Full Title: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy | |||||||||||||
Medical condition: limited-stage SCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FR (Completed) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005920-39 | Sponsor Protocol Number: UC-IMM-2106 | Start Date*: 2022-07-12 |
Sponsor Name:Unicancer | ||
Full Title: A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT) | ||
Medical condition: Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously un... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000929-42 | Sponsor Protocol Number: TCH-306 | Start Date*: 2021-06-09 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ... | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001065-21 | Sponsor Protocol Number: ET21-023 | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: PAXIPEM - Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) | |||||||||||||
Medical condition: Locally advanced or metastatic papillary cell carcinoma (PRCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014729-18 | Sponsor Protocol Number: 5442-012-00 | Start Date*: 2009-11-30 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Un Ensayo de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo y Comparador Activo, de Determinación del Rango de Dosis para Evaluar los Efectos de MK-5442 en la Densidad Mineral Ósea ... | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012926-35 | Sponsor Protocol Number: 5442-001-02 | Start Date*: 2009-09-28 | |||||||||||
Sponsor Name:Merck & Co, Inc. | |||||||||||||
Full Title: A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women with Osteoporosis | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002288-69 | Sponsor Protocol Number: CINC280A2203 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase II, Open-Label, Multicenter Study of Capmatinib in Participants with MET exon 14 skipping mutation positive, advanced, Non Small-Cell Lung Cancer that has metastasized to the Brain | |||||||||||||
Medical condition: cMET mutated NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000690-23 | Sponsor Protocol Number: ADVL0612;NCI-07-C-0220 | Start Date*: 2012-02-29 | |||||||||||
Sponsor Name:National Institution of Health (NCI) | |||||||||||||
Full Title: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors | |||||||||||||
Medical condition: Paediatric solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003907-20 | Sponsor Protocol Number: C16051 | Start Date*: 2019-07-10 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit | ||||||||||||||||||
Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract... | ||||||||||||||||||
Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001491-29 | Sponsor Protocol Number: Prodige52–UCGI29 | Start Date*: 2016-10-13 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting | |||||||||||||
Medical condition: High-risk stage III colon cancer in adjuvant setting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
